References
1. Karas DJ, Bandari J, Browning DN, Jacobs BL, Davies BJ. Payments to Pediatricians in the Sunshine Act. Clinical Pediatrics . 2017/07/01 2016;56(8):723-728. doi:10.1177/0009922816670981
2. Sampson MR, Benjamin DK, Cohen-Wolkowiez M. Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health. Expert review of clinical pharmacology . 2012;5(5):525-531. doi:10.1586/ecp.12.52
3. Medicine AFABoI, Medicine A-AFACoP-ASoI, European Federation of Internal M. Medical professionalism in the new millennium: a physician charter. Ann Intern Med . Feb 5 2002;136(3):243-6. doi:10.7326/0003-4819-136-3-200202050-00012
4. Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019.JAMA Oncology . 2021;7(3):440-444. doi:10.1001/jamaoncol.2020.6591
5. Pokorny AMJ, Fabbri A, Bero LA, Moynihan R, Mintzes BJ. Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review.British Journal of Cancer . 2021/10/01 2021;doi:10.1038/s41416-021-01552-1
6. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS One . 2020;15(10):e0239610. doi:10.1371/journal.pone.0239610
7. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg . Aug 17 2021;0(0):1945998211034724. doi:10.1177/01945998211034724
8. Ozaki A, Saito H, Onoue Y, et al. Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open . Sep 6 2019;9(9):e028805. doi:10.1136/bmjopen-2018-028805